RALLYBIO CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.7 USD | +3.03% |
|
-3.41% | -28.87% |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 70.46M 5.64B |
|---|---|---|---|---|---|
| Net income 2024 * | -66M -5.28B | Net income 2025 * | -63M -5.04B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 65.1M 5.21B | Net cash position 2025 * | 106M 8.46B | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.06
x | P/E ratio 2025 * |
-1.16
x | Employees | 43 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.48% |
More Fundamentals
* Assessed data
More news
Latest transcript on Rallybio Corporation
More recommendations
More press releases
| 1 day | +3.03% | ||
| 1 week | -3.41% | ||
| Current month | -8.11% | ||
| 1 month | +15.65% | ||
| 3 months | +22.30% | ||
| 6 months | -54.67% | ||
| Current year | -28.87% |
1 week
1.54
1.88
1 month
1.543.46
Current year
1.233.46
1 year
1.239.14
3 years
1.2325.78
5 years
1.2325.78
10 years
1.2325.78
| Managers | Title | Age | Since |
|---|---|---|---|
Martin MacKay
FOU | Founder | 68 | 31/12/17 |
Stephen Uden
FOU | Founder | 66 | 31/12/17 |
Jonathan Lieber
DFI | Director of Finance/CFO | 54 | 31/01/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ron Hunt
BRD | Director/Board Member | 59 | 28/02/19 |
Stephen Uden
FOU | Founder | 66 | 31/12/17 |
Martin MacKay
FOU | Founder | 68 | 31/12/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 0 M€ | 0.00% | - | |
| 0.00% | 18 M€ | +3.86% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.7 | +3.03% | 240,025 |
| 25/04/24 | 1.65 | +4.43% | 324,917 |
| 24/04/24 | 1.58 | -9.20% | 279,844 |
| 23/04/24 | 1.74 | -1.69% | 243,333 |
| 22/04/24 | 1.77 | +0.57% | 267,171 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.
Calendar
06/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.7
USD
Average target price
13
USD
Spread / Average Target
+664.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.87% | 70.46M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- RLYB Stock
